# Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Study · id `cardio:ct-nct02791230` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02791230](<https://clinicaltrials.gov/study/NCT02791230>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02791230

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1733 participants.

## Technical summary

Registry record NCT02791230. Allocation not applicable; no masking; primary purpose treatment. Start 2016-06-13 (actual); primary completion 2023-10-26 (actual). Results posted on 2025-02-03.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1733 participants (enrolled count; ClinicalTrials.gov record NCT02791230, source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)
- Started: 2016-06-13 (actual) (ClinicalTrials.gov record NCT02791230, source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)
- Primary completion: 2023-10-26 (actual) (ClinicalTrials.gov record NCT02791230, source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)
- Completion: 2023-11-02 (actual) (ClinicalTrials.gov record NCT02791230, source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)
- Results first posted: 2025-02-03 (ClinicalTrials.gov record NCT02791230, source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Czechia; France; Germany; Hong Kong SAR China; Italy; Japan; Netherlands; Spain; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT02791230, source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02791230-2025-02-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
- Condition: Transthyretin (TTR) Amyloid Cardiomyopathy
- Intervention (Drug): Tafamidis
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry intervention name matches this record: Tafamidis (`cardio:tafamidis`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: d69fc68f20d47695927d1d5cd2dd07865f03bdd3280acad4692b1867a310af62
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
